Masimo Corp Stock Price, News & Analysis

Masimo (NASDAQ: MASI) has announced the CE marking of its Rad-G™ with Temperature, a handheld device that features clinically proven SET® pulse oximetry, respiration rate measurement, and non-contact infrared thermometry. The device's robust design promotes portability and ease of use in various clinical settings. With a rechargeable battery lasting up to 24 hours, the Rad-G allows for continuous patient monitoring and assessment of vital signs. It aims to improve access to pulse oximetry for the five billion people lacking it, enhancing clinical decision-making.

Masimo (NASDAQ: MASI) will present at the Raymond James 42nd Annual Institutional Investors Conference on March 3, 2021, at 3:50 p.m. ET. The live presentation will be accessible via a webcast on the Masimo website, with a replay available afterward.

Masimo specializes in innovative medical technologies and monitoring solutions aimed at improving patient outcomes while reducing care costs. Its flagship product, Masimo SET^®, is trusted in over 100 million patients worldwide and is utilized in nine of the top ten U.S. hospitals, showcasing the company's impact on healthcare.

Masimo reported significant financial growth for Q4 2020 and the full year, with total revenue reaching $295.1 million in Q4, up 19.2% year-over-year, and $1,143.7 million for the year, a 22.0% increase. GAAP net income for Q4 rose to $70.7 million, or $1.21 per diluted share. However, operating margins decreased slightly, with GAAP operating margin at 22.0% for Q4 versus 24.9% the previous year. For 2021, the company projects total revenue of $1,200 million, reflecting a 4.9% growth forecast.

Masimo (NASDAQ: MASI) has launched softFlow®, a new pulmonary care therapy providing high-flow warmed and humidified gases for spontaneously breathing patients. The device, approved for use in hospitals and home settings, helps manage respiratory conditions, particularly in COVID-19 patients. softFlow operates without external air supply and features a dedicated flow path for safety. Supported by clinical data, it has shown improved patient outcomes, with capabilities to enhance comfort and facilitate communication. The technology is already being used globally since its first introduction in 2016.

Masimo (NASDAQ: MASI) will announce its fourth quarter and full year 2020 financial results on February 23, 2021, after the market closes. The conference call to discuss these results will take place at 1:30 p.m. PT (4:30 p.m. ET) with CEO Joe Kiani and CFO Micah Young. Interested parties can register via the provided link to obtain call details. Masimo is known for developing advanced medical monitoring technologies aimed at improving patient outcomes while reducing healthcare costs.

Masimo (NASDAQ: MASI) has launched the full market release of Masimo SafetyNet-OPEN™, an innovative web and mobile app designed to assist organizations in managing health risks associated with COVID-19 and other infectious diseases. This solution offers features such as risk screening, contact tracing, and recovery management, enabling businesses and institutions to safely bring back employees and maintain operations. Building on the success of the Masimo SafetyNet™ platform, this tool aims to enhance public health safety while integrating with healthcare providers when necessary.

Masimo (NASDAQ: MASI) announced its participation in the BTIG MedTech and Digital Health Conference on February 18, 2021, at 11:00 a.m. Eastern Time. A live webcast will be accessible via Masimo's website, with a replay available post-event. Masimo is a leader in medical technology, focusing on innovations such as pulse oximetry and patient monitoring solutions to enhance patient outcomes and lower care costs. Its flagship product, Masimo SET®, is used in over 100 million patients globally, proving critical in diverse clinical settings.

Masimo (NASDAQ: MASI) announced the successful acquisition of LiDCO Group Plc, a prominent provider of hemodynamic monitoring solutions, on February 2, 2021. This strategic acquisition involves 100% ownership of LiDCO, which was previously listed on the London Stock Exchange's AIM submarket. Founded in 1991, LiDCO specializes in noninvasive hemodynamic monitoring equipment, focusing on optimizing patient care and outcomes. As a newly formed private subsidiary, LiDCO aims to leverage Masimo's advanced healthcare technologies to enhance patient monitoring capabilities.

Masimo (NASDAQ: MASI) has launched iSirona™, a connectivity hub that enhances interoperability in medical settings. The hub connects up to six devices, routing data to the Masimo Hospital Automation™ platform for effective EMR integration and monitoring. Compatible with over 500 medical devices, iSirona minimizes manual charting and transcription errors, streamlining clinician access to patient data. Its compact design suits space-constrained areas like operating rooms, and an onboard battery ensures data continuity during power outages.